C. Michael Gibson on Muck Rack

C. Michael Gibson

  • Executive Board Member, EXCITE International
  • President and Chief Executive Officer, Baim Institute for Clinical Research
As seen in: Nature, JAMA (The Journal of the American Medical Association), Medscape, AHA/ASA Journals, Healio, Healio Cardiac/Vascular Intervention, Healio Cardiology, NewsBreak, HCP Live, Radiological Society of North America and
Non-Profit Founder/Leader | ❤️ Doc | Artist Scientist Educator | News Anchor clinicaltrialresults.org | RT ≠ endorse | Disclaimer: bit.ly/1mewZOF
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C. Michael

Contact C. Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies - Nature Reviews Cardiology

|
By C. Michael Gibson, Diana A. Gorog, Roxana Mehran, Rocco Montone
| Nature
Abstract Despite substantial advances in the secondary prevention of cardiovascular disease, atherosclerosis of the coronary arteries and its consequences remain the leading cause of death worldwide. Residual cardiovascular risk refers to the ongoing risk of recurrent cardiovascular events that persists in patients with coronary artery disease despite receiving optimal secondary prevention treatment and effective control of conventional risk factors.
Open in Who Shared Issue with article?

Cardiovascular Medicine 2025 Wrapped

|
By Robert Harrington, C. Michael Gibson
| Medscape
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. Robert A. Harrington, MD: Hi. I’m Bob Harrington from Weill Cornell Medicine here in New York City, and recording my favorite podcast of the year, which is the cardiology year in review, with my good friend Mike Gibson. We’ve done this for a number of years now.
Open in Who Shared Issue with article?

CeleBrate: Zalunfiban Administration at First Contact Improves STEMI Outcomes, With C. Michael Gibson, MD

|
By C. Michael Gibson
| consultantlive.com
Published on: Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.
Open in Who Shared View Duplicates (2) Issue with article?
See all 60 licensed articles (108 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with C. Michael

Contact C. Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified